Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause

NCT00195546 ↗

Phase 3 Completed 465 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedSingle-groupDouble-blindTreatment

Summary

Primary: To assess the efficacy and safety of DVS-233 SR compared with placebo for treatment of vasomotor symptoms (VMS) associated with menopause and to compare the bleeding incidence of DVS-233 SR and tibolone. Secondary: To assess the effects of DVS-233 SR and tibolone on changes from baseline in weight, breast pain, and health outcomes indicators.

Timeline

Start: 2005-04
Primary completion: —
Completion: 2006-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Desvenlafaxine	Other / unclassified	—	—

Indications

No indication recorded.